About: Unpolarized Release of Vaccinia Virus and HIV Antigen by Colchicine Treatment Enhances Intranasal HIV Antigen Expression and Mucosal Humoral Responses

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Unpolarized Release of Vaccinia Virus and HIV Antigen by Colchicine Treatment Enhances Intranasal HIV Antigen Expression and Mucosal Humoral Responses Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Unpolarized Release of Vaccinia Virus and HIV Antigen by Colchicine Treatment Enhances Intranasal HIV Antigen Expression and Mucosal Humoral Responses
Creator	Yang, Yi Li, Yaoming Zhang, Yan Cao, Yuan Chen, Yaoqing Han, Chen He, Benxia Li, Qiaoli Liu, Fang Sun, Ying Yan, Huimin Yang, Jingyi Zhong, Maohua Zhou, Dihan Bao, Rong Zhang, Citation
Source	Medline; PMC
abstract	The induction of a strong mucosal immune response is essential to building successful HIV vaccines. Highly attenuated recombinant HIV vaccinia virus can be administered mucosally, but even high doses of immunization have been found unable to induce strong mucosal antibody responses. In order to solve this problem, we studied the interactions of recombinant HIV vaccinia virus Tiantan strain (rVTT-gagpol) in mucosal epithelial cells (specifically Caco-2 cell layers) and in BALB/c mice. We evaluated the impact of this virus on HIV antigen delivery and specific immune responses. The results demonstrated that rVTT-gagpol was able to infect Caco-2 cell layers and both the nasal and lung epithelia in BALB/c mice. The progeny viruses and expressed p24 were released mainly from apical surfaces. In BALB/c mice, the infection was limited to the respiratory system and was not observed in the blood. This showed that polarized distribution limited antigen delivery into the whole body and thus limited immune response. To see if this could be improved upon, we stimulated unpolarized budding of the virus and HIV antigens by treating both Caco-2 cells and BALB/c mice with colchicine. We found that, in BALB/c mice, the degree of infection and antigen expression in the epithelia went up. As a result, specific immune responses increased correspondingly. Together, these data suggest that polarized budding limits antigen delivery and immune responses, but unpolarized distribution can increase antigen expression and delivery and thus enhance specific immune responses. This conclusion can be used to optimize mucosal HIV vaccine strategies.
has issue date	2011-09-15(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0024296
bibo:pmid	21935396
has license	cc-by
sha1sum (hex)	25615501bc9f54fd01b72047cec1f8ec619b1e69
schema:url	https://doi.org/10.1371/journal.pone.0024296
resource representing a document's title	Unpolarized Release of Vaccinia Virus and HIV Antigen by Colchicine Treatment Enhances Intranasal HIV Antigen Expression and Mucosal Humoral Responses
has PubMed Central identifier	PMC3174162
has PubMed identifier	21935396
schema:publication	PLoS One
resource representing a document's body	covid:25615501bc9f54fd01b72047cec1f8ec619b1e69#body_text
is schema:about of	named entity 'mucosal' named entity 'body' named entity 'impact' named entity 'cell' named entity 'budding' named entity 'unpolarized' named entity 'HIV vaccine' named entity 'HIV' named entity 'RESPONSES' named entity 'HAVE' named entity 'THESE' named entity 'HIV' named entity 'ORDER' named entity 'CONCLUSION' named entity 'BUILDING' named entity 'IMMUNIZATION' named entity 'SURFACES' named entity 'COLCHICINE' named entity 'ATTENUATED' named entity 'INFECTION' named entity 'STRAIN' named entity 'USED' named entity 'PROBLEM' named entity 'STRONG' named entity 'RELEASE' named entity 'ADMINISTERED' named entity 'EXPRESSED' named entity 'SPECIFIC' named entity 'RESPIRATORY SYSTEM' named entity 'EXPRESSION' named entity 'DEGREE' named entity 'IMMUNE RESPONSES' named entity 'RELEASED' named entity 'INTERACTIONS' named entity 'TO INFECT' named entity 'HIV ANTIGEN' named entity 'HIV VACCINE' named entity 'INCREASE' named entity 'STIMULATED' named entity 'VIRUS' named entity 'ANTIBODY' named entity 'HIGHLY' named entity 'LUNG' named entity 'STRATEGIES' named entity 'OPTIMIZE' named entity 'INDUCTION' named entity 'TREATING' named entity 'EXPRESSION' named entity 'IMPROVED' named entity 'IMMUNE RESPONSE' named entity 'WHOLE BODY' named entity 'ESSENTIAL' named entity 'NOT OBSERVED' named entity 'RECOMBINANT' named entity 'DELIVERY' named entity 'FOUND' named entity 'LAYERS' named entity 'ANTIGEN' named entity 'BALB' named entity 'INTRANASAL' named entity 'SUCCESSFUL' named entity 'EPITHELIAL CELLS' named entity 'HIV ANTIGENS' named entity 'MUCOSAL' named entity 'HIV VACCINES' named entity 'COLCHICINE TREATMENT'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software